Rebecca B. White

发表

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

K. K. Nanda, C. Lindsley, R. Spencer, 2017, Bioorganic & medicinal chemistry letters.

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

J. Vacca, C. Regan, Y. S. Tang, 2010, Journal of Pharmacology and Experimental Therapeutics.

Adenosine analogue inhibitors of S-adenosylhomocysteine hydrolase.

A. McCampbell, J. Majercak, Rena Zhang, 2014, Bioorganic & medicinal chemistry letters.

Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine.

H. Selnick, M. Fraley, D. Gauvreau, 2015, Bioorganic & medicinal chemistry letters.

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor

E. Hostetler, C. Regan, M. Fraley, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Benzimidazole CB2 agonists: design, synthesis and SAR.

K. K. Nanda, D. Henze, Suzie Yeh, 2014, Bioorganic & medicinal chemistry letters.

[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.

Sandra M. Sanabria-Bohórquez, L. Gantert, E. Hostetler, 2013, ACS medicinal chemistry letters.

MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.

J. Vacca, H. Selnick, S. Graham, 2012, Bioorganic & medicinal chemistry letters.

P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold.

Youwei Yan, L. Kuo, J. Vacca, 2005, Bioorganic & medicinal chemistry letters.

Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability.

J. Vacca, B. Wong, S. D. Lewis, 2004, Bioorganic & medicinal chemistry letters.

Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.

Youwei Yan, L. Kuo, J. Vacca, 2003, Bioorganic & medicinal chemistry letters.

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.

Daniel R McMasters, James C Barrow, W. M. Sanders, 2003, Journal of medicinal chemistry.

Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.

Lawrence C Kuo, Daniel R McMasters, James C Barrow, 2004, Journal of medicinal chemistry.

Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.

Kenneth D Anderson, K. K. Nanda, N. Liverton, 2006, Journal of medicinal chemistry.

9-hydroxyazafluorenes and their use in thrombin inhibitors.

Youwei Yan, B. Wong, P. Nantermet, 2005, Journal of medicinal chemistry.

Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.

K. K. Nanda, D. Henze, Suzie Yeh, 2011, Bioorganic & medicinal chemistry letters.

Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.

Youwei Yan, J. Vacca, B. Wong, 2006, Bioorganic & medicinal chemistry.

P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.

B. Wong, S. D. Lewis, E. A. Lyle, 2011, Bioorganic & medicinal chemistry letters.

Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.

N. Liverton, C. Claiborne, R. Spencer, 2010, Bioorganic & medicinal chemistry letters.

Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.

K. K. Nanda, C. Lindsley, R. Spencer, 2006, Bioorganic & medicinal chemistry letters.

Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.

D. Henze, Suzie Yeh, G. Hartman, 2011, Bioorganic & medicinal chemistry letters.

Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins.

T. Baillie, P. Pearson, B. Wong, 2003, Chemical research in toxicology.